-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
AEGON ASSET MANAGEMENT UK Plc Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)
AEGON ASSET MANAGEMENT UK Plc Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)
AEGON ASSET MANAGEMENT UK Plc reduced its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Get Rating) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 438,371 shares of the biotechnology company's stock after selling 32,440 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc owned 0.61% of Veracyte worth $8,719,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new position in shares of Veracyte during the first quarter worth $33,000. Quantbot Technologies LP acquired a new stake in Veracyte in the first quarter valued at $73,000. Lazard Asset Management LLC raised its holdings in Veracyte by 46.3% in the first quarter. Lazard Asset Management LLC now owns 3,410 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 1,079 shares in the last quarter. Prospera Financial Services Inc acquired a new stake in Veracyte in the first quarter valued at $127,000. Finally, Vienna Asset Management LLC acquired a new stake in Veracyte in the fourth quarter valued at $147,000.
Get Veracyte alerts:Veracyte Stock Performance
Shares of Veracyte stock traded down $0.33 during trading on Monday, hitting $18.14. 23,586 shares of the stock were exchanged, compared to its average volume of 938,363. The stock's fifty day moving average is $23.36 and its 200 day moving average is $22.39. The stock has a market cap of $1.30 billion, a PE ratio of -26.82 and a beta of 1.17. Veracyte, Inc. has a 12 month low of $14.85 and a 12 month high of $54.13.
Veracyte (NASDAQ:VCYT – Get Rating) last announced its earnings results on Tuesday, August 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.08. Veracyte had a negative net margin of 18.13% and a negative return on equity of 4.05%. The firm had revenue of $72.86 million during the quarter, compared to analyst estimates of $67.37 million. Sell-side analysts anticipate that Veracyte, Inc. will post -0.8 EPS for the current fiscal year.Analyst Upgrades and Downgrades
VCYT has been the topic of a number of research reports. Raymond James increased their target price on shares of Veracyte from $30.00 to $31.00 and gave the stock an "outperform" rating in a report on Thursday, August 4th. Needham & Company LLC increased their target price on shares of Veracyte from $26.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.
Veracyte Profile
(Get Rating)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Featured Articles
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Get Rating).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
AEGON ASSET MANAGEMENT UK Plc reduced its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Get Rating) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 438,371 shares of the biotechnology company's stock after selling 32,440 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc owned 0.61% of Veracyte worth $8,719,000 at the end of the most recent quarter.
据Veracyte,Inc.在提交给美国证券交易委员会的最新信息中称,Aegon资产管理英国公司在第二季度减持了6.9%的Veracyte,Inc.股票。该公司在本季度出售了32,440股后,持有438,371股这家生物技术公司的股票。截至最近一个季度末,Aegon资产管理公司UK Plc拥有Veracyte 0.61%的股份,价值8,719,000美元。
Several other institutional investors also recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new position in shares of Veracyte during the first quarter worth $33,000. Quantbot Technologies LP acquired a new stake in Veracyte in the first quarter valued at $73,000. Lazard Asset Management LLC raised its holdings in Veracyte by 46.3% in the first quarter. Lazard Asset Management LLC now owns 3,410 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 1,079 shares in the last quarter. Prospera Financial Services Inc acquired a new stake in Veracyte in the first quarter valued at $127,000. Finally, Vienna Asset Management LLC acquired a new stake in Veracyte in the fourth quarter valued at $147,000.
其他几家机构投资者最近也买卖了该公司的股票。Point72 Hong Kong Ltd在第一季度收购了价值33,000美元的Veracyte股票的新头寸。Quantbot Technologies LP在第一季度收购了Veracyte的新股份,价值7.3万美元。Lazard Asset Management LLC在第一季度将其在Veracyte的持股增加了46.3%。Lazard Asset Management LLC现在拥有3410股这家生物技术公司的股票,价值94,000美元,上个季度又购买了1,079股。普罗斯佩拉金融服务公司在第一季度收购了Veracyte的新股份,价值12.7万美元。最后,维也纳资产管理有限责任公司在第四季度收购了Veracyte的新股份,价值14.7万美元。
Veracyte Stock Performance
Veracyte股票表现
Shares of Veracyte stock traded down $0.33 during trading on Monday, hitting $18.14. 23,586 shares of the stock were exchanged, compared to its average volume of 938,363. The stock's fifty day moving average is $23.36 and its 200 day moving average is $22.39. The stock has a market cap of $1.30 billion, a PE ratio of -26.82 and a beta of 1.17. Veracyte, Inc. has a 12 month low of $14.85 and a 12 month high of $54.13.
在周一的交易中,Veracyte的股价下跌了0.33美元,跌至18.14美元。该股成交量为23,586股,而平均成交量为938,363股。该股的50日移动均线切入位为23.36美元,200日移动均线切入位为22.39美元。该股市值为13亿美元,市盈率为-26.82,贝塔系数为1.17。Veracyte,Inc.的12个月低点为14.85美元,12个月高位为54.13美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
VCYT has been the topic of a number of research reports. Raymond James increased their target price on shares of Veracyte from $30.00 to $31.00 and gave the stock an "outperform" rating in a report on Thursday, August 4th. Needham & Company LLC increased their target price on shares of Veracyte from $26.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.
VCYT已经成为许多研究报告的主题。雷蒙德·詹姆斯在8月4日周四的一份报告中将Veracyte的股票目标价从30.00美元上调至31.00美元,并给予该股“跑赢大盘”的评级。Needham&Company LLC在8月3日(星期三)的一份报告中将Veracyte的股票目标价从26.00美元上调至31.00美元,并给予该股“买入”评级。一名分析师对该股的评级为卖出,六名分析师对该股的评级为买入。根据MarketBeat的数据,该股目前的共识评级为“适度买入”,共识目标价为42.50美元。
Veracyte Profile
Veracyte配置文件
(Get Rating)
(获取评级)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Veracyte,Inc.是一家全球性的诊断公司。该公司提供Afirma基因组测序分类器和Xpression Atlas,用于确定结果不确定的患者是否为良性疾病,以避免不必要的手术;解密前列腺癌活检和根治性前列腺癌切除术;Prosigna乳腺癌检测用于乳腺癌诊断;Percepta基因组测序分类器和Percepta鼻拭子测试用于肺癌诊断;Envisia基因组分类器用于诊断间质性肺部疾病,包括特发性肺纤维化;免疫结肠癌检测用于结肠癌诊断。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免费获取StockNews.com关于Veracyte的研究报告(VCyT)
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
- 自动区重新进入拉力赛模式,新高在望
- Upwork股价跌入便宜货领域
- 克罗格百货是你的一站式消费者史泰博股票
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Get Rating).
想看看还有哪些对冲基金持有VCYT吗?访问HoldingsChannel.com获取Veracyte,Inc.(纳斯达克代码:VCyt-Get Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Veracyte Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Veracyte和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧